Benzinga | Jul 30, 2021 01:10PM EDT

Abbott Launches Latest Insertable Cardiac Monitor For Irregular Heart Rhythms

* Abbott Laboratories (NYSE:ABT) launched the Jot Dx, its latest insertable cardiac monitor (ICM), in the U.S.

* The technology allows for remote detection and improved diagnostic accuracy of cardiac arrhythmias in patients.

* Jot Dx offers clinicians and hospitals control of managing the flow of information through a feature that allows the viewing of abnormal heart rhythm data and provides the opportunity to simplify which irregular heart rhythms are recorded with a "key episodes" feature, according to a news release.

* Data presented at Heart Rhythm 2021 demonstrated that Jot Dx provides a 63% data reduction burden.

* Jot Dx ICM continuously monitors patient cardiac rhythms and connects directly to myMerlin, a downloadable mobile app that transmits real-time data to both the clinician and patient.

* Price Action: ABT shares are down 0.12% at $121.24 during the market session on the last check Friday.